Clinical Trial Update: Evaluation of Clinical Outcomes, Tolerability, and Costs of Avelumab Maintenance and Pembrolizumab Second-Line Therapy in Advanced Urothelial Cancer.

View source ↗

Summary

This clinical trial update reports on the outcomes, tolerability, and costs of using avelumab as maintenance therapy and pembrolizumab as second-line therapy in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Cancer

Drugs mentioned

• Avelumab (avelumab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Azienda Ospedaliera Universitaria Integrata Verona | Conditions: Urothelial Cancer | Status: COMPLETED